Lead Story
FDA clears first immunotherapy for locally advanced rectal cancer, opening a path to skip surgery entirely
On October 19, 2026, the FDA granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with previously untreated, MSI-H or dMMR locally advanced rectal cancer — the first immunotherapy approved for this setting, and four months ahead of its original target date. The approval rests on the phase 2 AZUR-1 trial, but the result drawing the most attention comes from an earlier 50-patient single-arm study in which 93% of patients maintained a complete clinical response at 12 months on dostarlimab alone, with none requiring chemoradiation or rectal surgery as part of their treatment. Because the approval is accelerated, GSK must continue following patients to confirm the responses translate into durable, long-term benefit, but the data raise the prospect that a meaningful share of patients with this cancer type could eventually avoid life-altering surgery altogether.
Read more →Lead Story
FDA clears first immunotherapy for locally advanced rectal cancer, opening a path to skip surgery entirely
On October 19, 2026, the FDA granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with previously untreated, MSI-H or dMMR locally advanced rectal cancer — the first immunotherapy approved for this setting, and four months ahead of its original target date. The approval rests on the phase 2 AZUR-1 trial, but the result drawing the most attention comes from an earlier 50-patient single-arm study in which 93% of patients maintained a complete clinical response at 12 months on dostarlimab alone, with none requiring chemoradiation or rectal surgery as part of their treatment. Because the approval is accelerated, GSK must continue following patients to confirm the responses translate into durable, long-term benefit, but the data raise the prospect that a meaningful share of patients with this cancer type could eventually avoid life-altering surgery altogether.
Immunotherapy combo nearly doubles five-year survival in advanced colorectal cancer, final trial data show
Final overall-survival results from the CheckMate 8HW trial, presented at the ESMO Congress in Madrid in late October, found that patients with first-line MSI-H/dMMR metastatic colorectal cancer treated with nivolumab plus ipilimumab had an estimated five-year survival rate of 77%, compared with 46% for those on standard chemotherapy. Median overall survival was not even reached in the combination arm after more than five years of follow-up, versus 50.1 months with chemotherapy, and severe treatment-related side effects were less frequent with the immunotherapy combination (22%) than with chemotherapy (51%). Researchers say the long-term data cement the dual-checkpoint regimen as a standard option for this biomarker-defined group of colorectal cancer patients.
Read more →Immunotherapy combo nearly doubles five-year survival in advanced colorectal cancer, final trial data show
Final overall-survival results from the CheckMate 8HW trial, presented at the ESMO Congress in Madrid in late October, found that patients with first-line MSI-H/dMMR metastatic colorectal cancer treated with nivolumab plus ipilimumab had an estimated five-year survival rate of 77%, compared with 46% for those on standard chemotherapy. Median overall survival was not even reached in the combination arm after more than five years of follow-up, versus 50.1 months with chemotherapy, and severe treatment-related side effects were less frequent with the immunotherapy combination (22%) than with chemotherapy (51%). Researchers say the long-term data cement the dual-checkpoint regimen as a standard option for this biomarker-defined group of colorectal cancer patients.
Saudi solar park doubles as a breeding sanctuary for threatened gazelles in a global-first program
At Red Sea Global's AMAALA destination on Saudi Arabia's coast, a 250-megawatt solar park has entered the breeding phase of ReWildingVoltaics, a program that uses the shaded, predator-secure space beneath and around solar arrays as habitat for threatened desert wildlife. Following a seven-month proof-of-concept that began in October 2025 with Sand gazelles, Mountain gazelles and Arabian hares, 33 female and five male Vulnerable Sand gazelles were introduced into the facility in May 2026, with the first offspring expected in December 2026. Organizers describe it as the first program of its kind anywhere, pairing renewable energy infrastructure directly with species recovery, and say the model could be adapted for other solar developments in arid regions.
Read more →Saudi solar park doubles as a breeding sanctuary for threatened gazelles in a global-first program
At Red Sea Global's AMAALA destination on Saudi Arabia's coast, a 250-megawatt solar park has entered the breeding phase of ReWildingVoltaics, a program that uses the shaded, predator-secure space beneath and around solar arrays as habitat for threatened desert wildlife. Following a seven-month proof-of-concept that began in October 2025 with Sand gazelles, Mountain gazelles and Arabian hares, 33 female and five male Vulnerable Sand gazelles were introduced into the facility in May 2026, with the first offspring expected in December 2026. Organizers describe it as the first program of its kind anywhere, pairing renewable energy infrastructure directly with species recovery, and say the model could be adapted for other solar developments in arid regions.
WWF's 'Science of Hope' report finds tigers, sea turtles and bluefin tuna rebounding even as wildlife overall declines
WWF and the Zoological Society of London released the Living Planet Report 2026 on October 8, subtitled 'The Science of Hope,' drawing on 35,803 population trends across 5,790 vertebrate species since 1970. While the report's headline figure is a sobering 73% average decline in monitored wildlife populations, it also finds that roughly half of those populations are stable or growing — about 43% increasing and 7% holding steady — and highlights specific recoveries including tigers, green sea turtles, Atlantic and Pacific bluefin tuna, and southern African elephants. Bluefin tuna populations in particular have recovered to the point that neither the Atlantic nor Pacific stock is now considered overfished, which WWF points to as evidence that targeted conservation and fisheries management can reverse even severe declines when sustained over decades.
Read more →WWF's 'Science of Hope' report finds tigers, sea turtles and bluefin tuna rebounding even as wildlife overall declines
WWF and the Zoological Society of London released the Living Planet Report 2026 on October 8, subtitled 'The Science of Hope,' drawing on 35,803 population trends across 5,790 vertebrate species since 1970. While the report's headline figure is a sobering 73% average decline in monitored wildlife populations, it also finds that roughly half of those populations are stable or growing — about 43% increasing and 7% holding steady — and highlights specific recoveries including tigers, green sea turtles, Atlantic and Pacific bluefin tuna, and southern African elephants. Bluefin tuna populations in particular have recovered to the point that neither the Atlantic nor Pacific stock is now considered overfished, which WWF points to as evidence that targeted conservation and fisheries management can reverse even severe declines when sustained over decades.
World Bank-backed Mission 300 connects over 50 million Africans to electricity in just two years
Mission 300, a joint push by the World Bank and African Development Bank launched in 2024 to bring electricity to 300 million people across Africa by 2030, passed the milestone of 50 million newly connected people in mid-2026, spanning roughly 40 countries. The initiative combines grid extensions, mini-grids and off-grid solar, and has drawn additional backing from philanthropic partners including the Rockefeller Foundation and the Global Energy Alliance for People and Planet, which have committed over $100 million toward accelerating electricity access. Officials and partner organizations caution that financing gaps remain a risk to hitting the 2030 target, but the pace of the first two years has been held up as evidence that large-scale electrification across the continent is achievable on a compressed timeline.
Read more →World Bank-backed Mission 300 connects over 50 million Africans to electricity in just two years
Mission 300, a joint push by the World Bank and African Development Bank launched in 2024 to bring electricity to 300 million people across Africa by 2030, passed the milestone of 50 million newly connected people in mid-2026, spanning roughly 40 countries. The initiative combines grid extensions, mini-grids and off-grid solar, and has drawn additional backing from philanthropic partners including the Rockefeller Foundation and the Global Energy Alliance for People and Planet, which have committed over $100 million toward accelerating electricity access. Officials and partner organizations caution that financing gaps remain a risk to hitting the 2030 target, but the pace of the first two years has been held up as evidence that large-scale electrification across the continent is achievable on a compressed timeline.